2022
DOI: 10.3389/fneur.2022.923310
|View full text |Cite
|
Sign up to set email alerts
|

Changes of brain function in patients with type 2 diabetes mellitus measured by different analysis methods: A new coordinate-based meta-analysis of neuroimaging

Abstract: ObjectiveNeuroimaging meta-analysis identified abnormal neural activity alterations in patients with type 2 diabetes mellitus (T2DM), but there was no consistency or heterogeneity analysis between different brain imaging processing strategies. The aim of this meta-analysis was to determine consistent changes of regional brain functions in T2DM via the indicators obtained by using different post-processing methods.MethodsSince the indicators obtained using varied post-processing methods reflect different neurop… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 173 publications
0
2
0
Order By: Relevance
“…5-6). Of the 100 included reviews, 32 related diabetes to cognitive function in mixed diabetic populations, 2,6,8, seven examined the effect of type 1 diabetes, 3,55-60 19 focused on type 2 diabetes, 5,7,61-77 14 observed brain structure in diabetes, 1,4,[78][79][80][81][82][83][84][85][86][87][88][89] two examined genetic and other biomarkers of dementia 90,91 and 26 focused on cognitive effects of antidiabetic treatment. 14,15,[20][21][22] Of the 27 studies included in the meta-analyses, 15 related metformin use to risk of dementia, [113][114][115][116][117][118][119][120][121][122][123][124][125][126][127] 10 were used in the thiazolidinedione metaanalysis, 113,[122][123][124][125][126][127][128]...…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…5-6). Of the 100 included reviews, 32 related diabetes to cognitive function in mixed diabetic populations, 2,6,8, seven examined the effect of type 1 diabetes, 3,55-60 19 focused on type 2 diabetes, 5,7,61-77 14 observed brain structure in diabetes, 1,4,[78][79][80][81][82][83][84][85][86][87][88][89] two examined genetic and other biomarkers of dementia 90,91 and 26 focused on cognitive effects of antidiabetic treatment. 14,15,[20][21][22] Of the 27 studies included in the meta-analyses, 15 related metformin use to risk of dementia, [113][114][115][116][117][118][119][120][121][122][123][124][125][126][127] 10 were used in the thiazolidinedione metaanalysis, 113,[122][123][124][125][126][127][128]...…”
Section: Resultsmentioning
confidence: 99%
“…5‐6). Of the 100 included reviews, 32 related diabetes to cognitive function in mixed diabetic populations, 2,6,8,26–54 seven examined the effect of type 1 diabetes, 3,55–60 19 focused on type 2 diabetes, 5,7,61–77 14 observed brain structure in diabetes, 1,4,78–89 two examined genetic and other biomarkers of dementia 90,91 and 26 focused on cognitive effects of antidiabetic treatment 14,15,20–22,92–112 . Of the 27 studies included in the meta‐analyses, 15 related metformin use to risk of dementia, 113–127 10 were used in the thiazolidinedione meta‐analysis, 113,122–130 four for pioglitazone, 126,129–131 seven for DPP‐4is, 123,125–127,132–134 five for α‐glucosidase inhibitors, 123,126,127,129,135 two for meglitinides, 126,129 seven for insulin, 122,123,125,127,129,136,137 11 for sulphonylureas,…”
Section: Resultsmentioning
confidence: 99%